אפיון תגובת מערכת החיסון ל- COVID-19 מתאפשרת בקלות בעזרת טכנולוגית Milliplex
שבה ניתן לכמת במדויק מספר רב של ציטוקינים במקביל בדוגמה ביולוגית אחת בלבד.
היתרונות בשיטה זו:
- דיוק גבוה וטווח דינאמי רחב
- פרוטוקול פשוט
- נפח דוגמה קטן
- מינימום שלבי Hands-on למניעת טעויות משתמש וחסכון בזמן
למידע נוסף:
בן לוי
[email protected]
050-9091984
MILLIPLEX® Multiplex Assays for Research Applications in COVID-19 (SARS-CoV-2
What is a “cytokine storm”?
When the immune system overreacts to a pathogen or other immunogenic substance such as a drug, a hyperinflammatory response may trigger excess production of signaling molecules from immune cells. This is referred to as cytokine storm syndrome (CSS) or cytokine release syndrome (CRS). Acute or systemic inflammation results in fluid buildup in the lungs, respiratory distress, multiple organ failure, and can be fatal.
How does a cytokine storm relate to COVID-19 (SARS-CoV-2)?
In response to SARS-CoV-2 viral infection of the lungs, a cytokine storm can result. Over-produced immune cells and their signaling molecules cause a local inflammatory response in the lungs leading to respiratory distress and reduced blood oxygen levels. A cytokine storm can contribute to severe clinical symptoms and poor patient outcomes.
Some early publications on the cytokine profile for COVID-19 have found increased levels of IL- 2, IL-7, G-CSF, IP-10, MCP-1, MIP-1α, TNFα, and Ferritin 1. In a separate study, IL-6 was also found to increase with SARS-CoV-2 infection 2. Tocilizumab, an immunosuppressive monoclonal antibody therapy that targets the IL-6 receptor (IL-6R) has been approved for Phase III clinical trials by the FDA to evaluate its effectiveness for the treatment of severe COVID-19 pneumonia as of March 26, 2020. IL-1β, IL- 1RA, IL-8, IL-9, IL-10, FGF-basic, GM-CSF, IFNγ, MIP-1β, PDGF, and VEGF have also been shown to be increased in COVID-19 patients compared to healthy subjects 3.
CSS research with non-human primate models
Research on SARS-CoV-2 is also being conducted in nonhuman primates such as rhesus macaques, which will allow researchers to test possible vaccines and antiviral medications/treatments in relevant animal models. A preprint article used MILLIPLEX® nonhuman primate assays to analyze serum over multiple time points in macaques with SARS-CoV-2 exposure for changes in cytokine and chemokine levels, and showed increases in IL-1RA, IL-6, IL-10, IL-15, MCP-1, MIP-1β, along with a decrease in TGFα 4.
Using MILLIPLEX® multiplex immunoassays to understand the immune response to COVID-19
Our MILLIPLEX® multiplex immunoassays offer researchers the ability to simultaneously quantitate a large number of analytes critical to understanding the immune response in humans. Our 48-plex Human Cytokine/Chemokine/Growth Factor Panel A saves time and sample volume for a snapshot of analyte profiles during a cytokine storm, sepsis, or other disease states. We offer a wide array of MILLIPLEX® soluble protein panels and cell signaling kits to help elucidate the downstream signaling pathways when researching antiviral immune response. Our portfolio offers the widest range of analytes across the most species, including nonhuman primate panels for vaccine research.
References
1. Mehta, P., et al. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Published Online March 12, 2020 https://doi.org/10.1016/S0140-6736(20)30630-9
2. Ruan, Q., et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med (2020). https://doi.org/10.1007/s00134-020- 05991-x
3. Huang, C., et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Published Online January 24, 2020 https://doi.org/10.1016/S0140-6736(20)30183-5
4. Munster, V., et al. 2020. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. bioRxiv 2020.03.21.001628; doi: https://doi. org/10.1101/2020.03.21.001628. This article is a preprint and has not been certified by peer review